Applied Therapeutics, Inc. (APLT)

8.89 -0.01 (-0.06%) As of 01:12PM EDT. Market open.

Applied Therapeutics, Inc.

545 Fifth Avenue
Suite 1400
New York, NY 10017
United States
212 220 9226
https://www.appliedtherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 31

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Shoshana Shendelman Ph.D.	Chair of the Board of Directors, Founder, President, CEO & Secretary	946.08k	N/A	1979
Mr. Les D. Funtleyder	CFO, Principal Financial Officer & Independent Director	48.75k	N/A	1971
Dr. Riccardo Perfetti M.D., Ph.D.	Chief Medical Officer	860.76k	N/A	1961
Mr. Constantine Chinoporos	COO & Chief Business Officer	N/A	N/A	1966
Ms. Catherine Thorpe	Chief Accounting Officer	N/A	N/A	1964
Mr. Corwin Dale Hooks	Chief Commercial Officer	N/A	N/A	1967

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Corporate Governance

Applied Therapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 10. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.